<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961180</url>
  </required_header>
  <id_info>
    <org_study_id>24638418</org_study_id>
    <nct_id>NCT01961180</nct_id>
  </id_info>
  <brief_title>The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS</brief_title>
  <official_title>The Effect of Cipralex in Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marianne Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To investigate the effect of Cipralex versus placebo on stress hormones, glucose
      metabolism, physical and mental health and quality of life in polycystic ovary
      syndrome(PCOS).

      Treatment: 2x20 women for 12 weeks. Design: Double blinded, randomized, placebo controlled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We want to investigate the effect of Cipralex versus placebo on stress hormones, glucose
      metabolism, physical and mental health and quality of life in polycystic ovary
      syndrome(PCOS).

      PCOS is characterized by menstrual deregulation, high testosterone, mail hair growth and
      increased stress hormones from the adrenals. Furthermore there are changes similar to those
      seen in diabetes.

      Cipralex is known to decrease stress hormones. But no investigations are on the effect of
      cipralex on PCOS, or how the increased stress hormones affect the PCOS condition.

      We will examine 2x20 women with PCOS. They will be randomized to Cipralex or placebo.
      Treatment duration is 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by questionaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of cortisone in 24 hour urine sample</measure>
    <time_frame>June 2013 to October 2015</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cortisone and cortisone metabolites, measured by 24 hour urine sample.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>June 2013 to October 2015</time_frame>
    <safety_issue>No</safety_issue>
    <description>measures bu 3 hour Glucose Tolerance Test, and homeostasis model assessment-insulin resistance(HOMA-IR)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Cipralex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipralex</intervention_name>
    <description>the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.</description>
    <arm_group_label>active comparator</arm_group_label>
    <other_name>Escitalopram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;25 and &lt;50

          -  Age &lt; 50

          -  PCOS

        Exclusion Criteria:

          -  Epilepsia

          -  use of metformin or oral anticonceptives

          -  pregnancy/breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne MD Andersen, sponsor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne MD Andersen, sponsor</last_name>
    <phone>004565411541</phone>
    <email>marianne.andersen1@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magda Lambaa MD Altinok, PhD-student</last_name>
    <phone>004524638418</phone>
    <email>magda.lambaa.altinok@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne MD Andersen, sponsor</last_name>
      <phone>004565411541</phone>
      <email>marianne.andersen1@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Magda Lambaa MD Altinok, phd-student</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Andersen</investigator_full_name>
    <investigator_title>PhD, chief physisian</investigator_title>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Adrenal hyper activity</keyword>
  <keyword>Glucose metabolism</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
